Skip to main
DOCS

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 24%
Buy 24%
Hold 43%
Sell 10%
Strong Sell 0%

Bulls say

Doximity is a promising company with strong fundamentals and positive market reception. Its online platform for physicians and healthcare professionals provides multiple solutions, such as collaboration tools, career management, and virtual patient visits. The company's recent strong financial results and increased revenue guidance, driven by its AI search and Insights products, showcase its potential for growth in the healthcare market. With a strong leadership team in place and continued investments in AI and brand marketing, Doximity is well-positioned for success in the coming years.

Bears say

Doximity is a healthcare technology company providing an online platform for physicians and other healthcare professionals to collaborate and stay updated on the latest medical news and research. However, despite its strong user base, the company's core marketing solutions segment may face challenges from a declining number of pharmaceuticals under patent, potentially reducing revenue opportunities. Additionally, Doximity's recent investments in AI technologies may result in lower short-term profits and market share gains. The company's FY27 outlook for revenue and adjusted EBITDA is below consensus estimates, and its ability to grow above the industry market rate may be limited due to the delayed launch of its AI search commercial product.

Doximity (DOCS) has been analyzed by 21 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 24% recommend Buy, 43% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Buy based on their latest research and market trends.

According to 21 analysts, Doximity (DOCS) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.